Ligand Pharmaceuticals Incorporated (LGND)Healthcare | Biotechnology | Jupiter, United States | NasdaqGM
303.53 USD
-7.60
(-2.443%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 303.53 |
Hot Take ↕ | Oct. 10, 2026, 1:18 a.m. EDT
Ligand presents a compelling long-term investment case driven by exceptional operational metrics, including robust revenue expansion and industry-leading profit margins, yet the immediate path forward is clouded by capital structure adjustments and insider activity. While the company maintains a fortress-like balance sheet with net cash on hand, the recent decision to issue convertible notes and the concurrent sale of stock by directors introduce friction that tempers near-term enthusiasm. The stock is trading near its yearly highs, supported by a strong trend relative to its 200-day average, but statistical models currently flag a weak bearish lean for the coming month. Investors should view this as a high-conviction growth story that requires patience, acknowledging that the premium valuation demands continued execution to justify the price. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.045667 |
| AutoTheta | 0.163988 |
| MSTL | 0.207122 |
| AutoARIMA | 0.210371 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 5.73 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.666 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2010-07-01 |
| Last Dividend Date | 2007-04-02 |
| Debt to Equity Ratio | 116.944 |
| Revenue per Share | 14.752 |
| Market Cap | 6,051,055,104 |
| Trailing P/E | 31.98 |
| Forward P/E | 25.40 |
| Beta | 1.01 |
| Profit Margins | 67.88% |
| Website | https://www.ligand.com |
As of Oct. 10, 2026, 1:18 a.m. EDT: Speculators are positioning for significant upside potential over the next two years, evidenced by heavy out-of-the-money call open interest in 2027 expirations. However, there is a distinct hedging signal in late 2026, with elevated implied volatility on December puts and substantial put open interest at lower strikes, suggesting a fear of near-term volatility despite the bullish long-term skew.
| Date | Dividend | Yield % |
|---|---|---|
| 2007-04-03 | 9.357455 | 33.068783 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.71971035 |
| Address1 | 555 Heritage Drive |
| Address2 | Suite 200 |
| All Time High | 326.63 |
| All Time Low | 4.11728 |
| Ask | 396.53 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 280,190 |
| Average Daily Volume3 Month | 257,996 |
| Average Volume | 257,996 |
| Average Volume10Days | 280,190 |
| Beta | 1.008 |
| Bid | 216.6 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 48.57 |
| City | Jupiter |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 303.53 |
| Current Ratio | 31.178 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 311.72 |
| Day Low | 300.23 |
| Debt To Equity | 116.944 |
| Display Name | Ligand Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Growth | 8.25 |
| Earnings Quarterly Growth | 9.008 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | 133,011,000 |
| Ebitda Margins | 0.4578 |
| Enterprise To Ebitda | 43.791 |
| Enterprise To Revenue | 20.048 |
| Enterprise Value | 5,824,750,592 |
| Eps Current Year | 9.30548 |
| Eps Forward | 11.94976 |
| Eps Trailing Twelve Months | 9.49 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,278,028,800 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 292.5114 |
| Fifty Day Average Change | 11.018585 |
| Fifty Day Average Change Percent | 0.037668906 |
| Fifty Two Week Change Percent | 71.97104 |
| Fifty Two Week High | 326.63 |
| Fifty Two Week High Change | -23.100006 |
| Fifty Two Week High Change Percent | -0.070722245 |
| Fifty Two Week Low | 175.89 |
| Fifty Two Week Low Change | 127.64 |
| Fifty Two Week Low Change Percent | 0.7256808 |
| Fifty Two Week Range | 175.89 - 326.63 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 722,097,000,000 |
| Float Shares | 19,487,257 |
| Forward Eps | 11.94976 |
| Forward P E | 25.400509 |
| Free Cashflow | 139,748,880 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 47 |
| Fullday Change | -7.600006 |
| Fullday Change Percent | -2.4427109 |
| Fullday Price | 303.53 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.81198996 |
| Gross Profits | 235,916,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0232 |
| Held Percent Institutions | 1.1610501 |
| Implied Shares Outstanding | 19,935,609 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investor.ligand.com/Investors/Investor-Overview/default.aspx |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,175,558,400 |
| Last Dividend Value | 9.357455 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,667,347,200 |
| Last Split Factor | 1,603:1000 |
| Long Business Summary | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. |
| Long Name | Ligand Pharmaceuticals Incorporated |
| Market | us_market |
| Market Cap | 6,051,055,104 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_30820 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 197,220,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,957,956,105 |
| Number Of Analyst Opinions | 12 |
| Open | 311.72 |
| Operating Cashflow | 131,714,000 |
| Operating Margins | 0.13488 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.53 |
| Phone | 858 550 7500 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 303.53 |
| Post Market Time | 1,791,921,640 |
| Previous Close | 311.13 |
| Price Eps Current Year | 32.618416 |
| Price Hint | 2 |
| Price To Book | 6.249331 |
| Price To Sales Trailing12 Months | 20.826782 |
| Profit Margins | 0.6788 |
| Quick Ratio | 30.826 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -7.60001 |
| Regular Market Change Percent | -2.44271 |
| Regular Market Day High | 311.72 |
| Regular Market Day Low | 300.23 |
| Regular Market Day Range | 300.23 - 311.72 |
| Regular Market Open | 311.72 |
| Regular Market Previous Close | 311.13 |
| Regular Market Price | 303.53 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 196,558 |
| Return On Assets | 0.039920002 |
| Return On Equity | 0.21962 |
| Revenue Growth | 0.337 |
| Revenue Per Share | 14.752 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 19,935,609 |
| Shares Percent Shares Out | 0.13430001 |
| Shares Short | 2,677,998 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,480,981 |
| Short Name | Ligand Pharmaceuticals Incorpor |
| Short Percent Of Float | 0.1611 |
| Short Ratio | 10.56 |
| Source Interval | 15 |
| State | FL |
| Symbol | LGND |
| Target High Price | 397.0 |
| Target Low Price | 247.0 |
| Target Mean Price | 344.25 |
| Target Median Price | 345.0 |
| Total Cash | 1,357,757,952 |
| Total Cash Per Share | 68.107 |
| Total Debt | 1,131,453,056 |
| Total Revenue | 290,542,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 9.49 |
| Trailing P E | 31.984194 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 244.87096 |
| Two Hundred Day Average Change | 58.659042 |
| Two Hundred Day Average Change Percent | 0.23955083 |
| Type Disp | Equity |
| Volume | 196,558 |
| Website | https://www.ligand.com |
| Zip | 33,458 |